Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.
Lafeuillade
A
A
Halfon
P
P
Chadapaud
S
S
Hittinger
G
G
Khiri
H
H
Poggi
C
C
D019380:Anti-HIV Agents / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016049:Didanosine / Q000627:therapeutic use; D018450:Disease Progression; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D018655:Lymphocyte Count; D009017:Morbidity; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D012367:RNA, Viral; D019259:Lamivudine; D015215:Zidovudine; D016049:Didanosine; D019258:Saquinavir; D019438:Ritonavir